

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/35, C07K 14/00	A1	(11) International Publication Number: WO 99/16467 (43) International Publication Date: 8 April 1999 (08.04.99)
(21) International Application Number: PCT/SE98/01765 (22) International Filing Date: 30 September 1998 (30.09.98) (30) Priority Data: 9703531-5 30 September 1997 (30.09.97) SE (71) Applicant: PHARMACIA & UPJOHN DIAGNOSTICS AB [SE/SE]; S-751 82 Uppsala (SE). (71)(72) Applicant and Inventor: VALENTA, Rudolf [AT/AT]; Beethovenstrasse 18, A-2604 Theresienfeld (AT). (72) Inventors: VRTALA, Susanne; Schenkendorfgasse 14-16/1/9, A-1210 Vienna (AT). VANGELISTA, Luca; Via Carlo Dottori, 5, I-35122 Padova (IT). EICHLER, Hans-Georg; Neuwaldeggerstrasse 41/5, A-1170 Vienna (AT). SPERR, Wolfgang, R.; Iglaseegasse 9, A-1190 Vienna (AT). VALENT, Peter; Schulgasse 7/18, A-1170 Vienna (AT). EBNER, Christof; Heinrich Albrechtgasse 19/1, A-2345 Brunn am Gebirge (AT). KRAFT, Dietrich; Rebenweg 1/18/1, A-1170 Vienna (AT). GRÖNLUND, Hans; Vinkelvägen 14, S-181 57 Lidingö (SE). (74) Agents: WIDÉN, Björn et al.; Pharmacia & Upjohn AB, Patent Dept., S-751 82 Uppsala (SE).		(81) Designated States: JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: NON-ANAPHYLACTIC FORMS OF ALLERGENS AND THEIR USE (57) Abstract An immunogen derived from a protein allergen comprises: a) a polymeric form of a non-anaphylactic immunogenic recombinant fragment of the protein allergen, said fragment containing an IgG epitope partly but not wholly overlapping an IgE epitope of the protein allergen, in which polymeric form said fragment constitutes the monomeric units; or b) a recombinant polymeric form of said protein allergen in which the protein allergen constitutes the monomeric units. The immunogen may be used for in vitro diagnosis of type I allergy and hyposensitization.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

NON-ANAPHYLACTIC FORMS OF ALLERGENS AND THEIR USE**Technical field and background**

The present invention concerns non-anaphylactic forms of
5 protein allergens and the use of the forms for
hyposensitization and for determining antibodies (IgA, IgD,
IgE, IgG, IgM) directed against the allergen, for instance
in the context of diagnosing in vitro type I allergy (IgE
mediated allergy). The invention also concerns a method for
10 hyposensitization of a mammalian individual, typically a
human individual, suffering from type I allergy against a
protein allergen.

The invention primarily concerns treating and diagnosing
15 humans.

By a protein allergen is meant any protein/polypeptide
causing a type I mediated allergic reaction. Thus the term
encompasses any naturally occurring protein allergen
20 including the smallest fragments thereof that will cause a
type I allergic reaction in a mammal, most importantly
humans.

In April 1997, the present inventors published an article
25 dealing with non-anaphylactic fragments of the Bet v 1
allergen. See Vrtala et al., "Conversion of the major birch
pollen allergen, Bet v 1, into two non-anaphylactic T cell
epitope containing fragments", J. Clin. Invest. 99(7) April
1997, 1673-1681.

30 Type I allergy represents a major health problem in
industrialised countries where more than 20 % of the
population suffer from Type I allergic reactions (allergic
rhinitis, conjunctivitis, allergic asthma and anaphylactic
35 shock) (Kaplan (ed) Allergy. Churchill Livingstone, New York
(1985)). Environmental proteins from pollen, mites and
animal dander belong to the major components which induce
release of biological mediators (e.g. histamine) by

crosslinking effector cell (mast cell, basophil) bound specific IgE antibodies. The production of specific IgE from B-cells is stimulated by allergen specific T-helper cells which in their majority belong to the TH2 type (Romagnani, Immunol. Today 13 (1992) 379-381). Therapy of Type I allergic diseases is currently performed by pharmacological treatment and by specific immunotherapy. Specific immunotherapy has been established already early in this century (Noon, Lancet 1 (1911) 1572-1573) and involves the systemic application of increasing doses of allergens for extended periods. Although specific immunotherapy is recognized as effective treatment, the occurrence of anaphylactic side effects represents one of the major disadvantages of this therapy. To reduce anaphylactic reactions the use of T-cell epitopes has recently been proposed for allergen specific immunotherapy (Briner et al., Proc. Natl. Acad. Sci. USA 90 (1993) 7608-7612, and Norman, Curr. Opin. Immunol. 5 (1993) 986-973).

Allergens harbour a great variety of different T-cell epitopes (Ebner et al., J. Immunol 150 (1993) 1047-1054; Joost-van-Neerven et al., J. Immunol. 151 (1993) 2326-2335; and Schenket al., J. Allergy Clin. Immunol. 96 (1995) 986-996) which may overlap with continuous IgE-epitopes. To prevent crosslinking of effector cell (mast cell, basophil) bound IgE and mediator release, T-cell epitopes and IgE epitopes need to be dissected. Following the concept of converting a major allergen into a T-cell vaccine, the present inventors selected Bet v 1 (Breiteneder et al., EMBO J. 8 (1989) 1935-1938), the major birch pollen allergen, as a model.

Bet v 1 was selected because epitope analysis indicated that it forms conformational IgE epitopes (Visco et al., J. Immunol. 157 (1996) 956-962; and Laffer et al., J. Immunol. 157 (1996) 4953-4962). In addition, Bet v 1 represents one of the most common allergens which is recognized by 95% of

tree pollen and food allergic individuals and almost 60% of them are sensitized exclusively against Bet v 1 (Jarolim et al., Allergy 44 (1989) 385-394). The cDNA coding for Bet v 1 has recently been isolated (Breiteneder et al., EMBO J. 8
5 (1989) 1935-1938) and recombinant Bet v 1 was expressed in Escherichia coli (Valenta et al., J. Allergy Clin. Immunol. 88 (1991) 889-894; and Ferreira et al., J. Biol. Chem. 268 (1993) 19574-19580). Recombinant Bet v 1 has been shown to possess an IgE-binding capacity similar to that of natural
10 Bet v 1 and shares IgE as well as T-cell epitopes with Bet v 1 homologous proteins present in pollen from various trees and plant derived foods (Ebner et al., J. Allergy Clin. Immunol. 95 (1995) 962-969; Ebner et al., J. Immunol. 150 (1993) 1047-1054; and Schenk et al., Eur. J. Biochem. 224
15 (1994) 717-724). The biological activity of the recombinant Bet v 1 has been demonstrated by histamine release experiments and by skin prick testing of allergic patients (Valenta et al., J. Allergy Clin. Immunol. 91 (1993) 88-97; Pauli et al., J. Allergy Clin. Immunol. 98 (1996) 1100-1109;
20 and Menz et al., Clin. Exp. Allergy 26 (1995) 50-60).

The invention.

A first aspect of the present invention is an immunogen derived from a protein allergen. It has a strongly reduced
25 anaphylactic ability compared to the protein allergen from which it derives and will therefore in the context of the present invention be called non-anaphylactic. The immunogen is characterized in that it comprises:

- 30 a) a polymeric form of a non-anaphylactic immunogenic recombinant fragment of the protein allergen, said fragment containing an IgG epitope partly but not wholly overlapping an IgE epitope of the protein allergen, in which polymeric form the fragment constitutes the monomeric units; or

b) a recombinant polymeric form of said protein allergen in which the protein allergen constitutes the monomeric units.

- 5 Thus, in accordance with the present invention, the IgE-binding capacity of an allergen is reduced by genetic fragmentation or polymerization.

In the above-mentioned non-anaphylactic (or hypoallergic)
10 allergen fragment, the IgE epitope epitope has been broken up by fragment formation. By the term "a broken up IgE epitope" is meant that the fragment formation has resulted in a fragment that only contains a part of the corresponding IgE epitope present in the starting protein allergen. The
15 epitopes in question may be either conformational or linear, with particular emphasis for the IgE epitope being conformational in case of a fragment according to polymeric form (a) above. Compare Bet v 1 fragments aa 1-74 and 75-160 as described in the experimental part herein and by Vratala
20 et al., J. Clin. Invest. 99(7) April 1997, 1673-1681.

Preferably, the fragment is larger than 15 amino acids. The maximum size of the fragment varies depending on the specific allergen. Usually, the maximum size may be said to
25 be the largest fragment of the allergen that can be produced without yielding anaphylactic reactions corresponding to 10% of the reaction induced by the complete allergen (as determined by skin testing or basophil histamine release).

30 By polymeric forms means that the immunogen typically comprises 2-10 of the monomeric units defined in (a) and (b) above. At the priority date results had been obtained with polymeric forms containing 2, 3 and 4 monomeric units.

35 The immunogens (a) and (b) may be produced by recombinant techniques to directly give the polymeric forms according to (a) and (b). For (a) the polymeric form may also be

accomplished by covalently linking two or more identical recombinant fragment molecules, optionally to a common carrier molecule. In the final immunogen that is to be used for hyposensitization therapy or in vitro assays, the
5 polymeric forms according to (a) and (b) may have been linked to a carrier in order to increase the immunogenicity. In case this carrier is a protein and one wants to have a linear immunogen it is possible to produce the immunogen in one step by expression of the corresponding gene construct
10 in the appropriate host cell, such as a procaryotic (e.g. E. coli) or eucaryotic (yeast or a mammalian cell line) cell. See further Scheiner O and Kraft D, Allergy 50 (1995) 384-391; and Valenta R and Kraft D, Current Opinion in Immunology 7 (1995) 751-756.

15 By the use of recombinant techniques it is easy to introduce oligopeptide linkers between each monomeric unit of the polymeric forms of the immunogen according to (a) and (b), respectively. Suitable amino acid residues in the linker may
20 be selected among hydrophobic or hydrophilic or among basic, acid or neutral amino acids. Hydrophobic amino acids are Trp, Gly, Ala, Phe, Pro, Met, Val, Leu, and Ile. Hydrophilic amino acids are for instance Gln, Ser, Gly, Glu, Pro, His and Arg. The length of the oligopeptide linker typically is
25 an integer in the interval 0-30, such as in the interval 0-10, amino acid residues. At the priority date, the preferred linker was the tripeptide Leu-Val-Pro.

In the experimental part the invention is illustrated with
30 the birch pollen allergen Bet v 1.

A second aspect of the invention is a specific hyposensitization therapy. This therapy may be performed as known in the art for protein allergens and encompasses
35 administering repeatedly to the mammal, typically a human individual, suffering from type I allergy against the protein allergen an immunogen that is capable of raising an

IgG immune response against the protein allergen. Administration may be done systemically, for instance by injection, infusion, etc, but also the oral route has been suggested in order to expose the intestinal part of the immune system. The immunogen may be admixed with suitable adjuvants such as aluminium oxide. See further Norman PS, "Current status of immunotherapy for allergies and anaphylactic reactions" Adv. Internal. Medicine 41 (1996) 681-713.

10

A third aspect of the invention is to use the immunogen of the first aspect, in particular according to form (b), as an antigen in an immunoassay for detecting specific antibodies of the IgA, IgD, IgE, IgG or IgM class directed against the protein allergen or protein allergens from which the immunogen derives. Appropriate assay variants involve formation of a ternary immune complex between the immunogen, sample antibody and an antibody directed against the Ig-class of interest. The sample may be any Ig-containing biological fluids, for instance a blood derived sample (serum, plasma, whole blood), CSF, etc.

The invention will be defined in the attached claims that are part of the specification. The invention will now be illustrated by three non-limiting Examples.

EXPERIMENTAL PART

Example 1. Bet v 1 polymers

30

Construction of the Bet v 1-polymers

The Bet v 1-cDNA (Breiteneder et al., "The gene coding for the major birch pollen allergen Bet v 1 is highly homologous to a pea resistance response gene", EMBO J. 8 (1989)

1935-1938) was PCR-amplified with the following oligonucleotide primers:

Bet v 1-dimer:

For construction of the first Bet v 1-segment:

Sequence Id No 1:

5 5'GAG GAA TTC CAT ATG GGT GTT TTC AAT TAC3'

Eco RI Nde I

Sequence Id No 2:

5'CGG GGT ACC AAG TTG TAG GCA TCG GAG TG3'

Kpn I

10

For construction of the second Bet v 1-segment:

Sequence Id No 3:

5'CGG GGT ACC GAT GGG TGT TTT CAA TTA C3'

Kpn I

15

Sequence Id No 4:

5'CCG GAA TTC CCG CTC GAG CTA TTA GTT GTA GGC ATC GGA GTG3'

Eco RI Xho I

Bet v 1-trimer:

20

First Bet v 1-segment:

The same primers were used as for construction of the first segment of Bet v 1-dimer.

25 Second Bet v 1-segment:

Sequence Id No 5:

5'CGG GGT ACC GAT GGG TGT TTT CAA TTA C3'

Kpn I

Sequence Id No 6:

30 5'CGG AAT TCA CTA GTG GGT TGT AGG CAT CGG AGT G3'

Eco RI Spe I

Third Bet v 1-segment:

Sequence Id No 7:

35 5'CCG GAA TTC GGA CTA GTA ATG GGT GTT TTC AAT TAC3'

Eco RI Spe I

Sequence Id No 8:

5'CGG AAT TCG TTG TAG GCA TCG GAG TG3'

Eco RI

- 5 **Protocol for PCR-amplification.** Reaction mix (GeneAmp PCR kit, Perkin Elmer, Branchburg, N.J. USA): 44µl H₂O_{dd}, 10x1 10x PCR buffer, 4µl 5mM dATP, 4µl 5mM dCTP, 4µl 5mM dGTP, 4µl 5mM dGTP, 4µl 25mM MgCl₂, 3µl 10xM primer 1, 3µl 10xM primer 2, 10µl 1ng/µl Bet v 1. 10x PCR-buffer: 100mM Tris-
10 HCl, pH 8.3, and 500 mM KCl. The reaction mixture was heated for 5 minutes at 94°C, afterwards 35 cycles of 1min at 94°C, 2min at 40°C, and 3 min at 72°C were performed. During the first cycle 10µl of AmpliTaq DNA Polymerase (2.5 U/10µl) were added.
- 15 After PCR-amplification, the PCR-products were digested with the corresponding restriction enzymes. Primers which contained additional Eco RI sites, were digested first with Eco RI to facilitate subcloning. Digested fragments were
20 purified using Nick columns (Pharmacia Biotech AB, Uppsala, Sweden), and ligated into pET-17b plasmids (Novagen, Madison, USA). The plasmid, containing the first Bet v 1-segment, was further digested with Kpn I/Xho I in the case of Bet v 1-dimer, or with Kpn I/Spe I in the case of Bet v
25 1-trimer, to obtain vectors, in which the second Bet v 1-segments could be incorporated. In the case of Bet v 1-trimer, this construct was further digested with Spe I/Eco R I and the third Bet v 1-segment was added.
- 30 **Expression and purification of recombinant Bet v 1-polymers**
Recombinant Bet v 1-dimer and recombinant Bet v 1-trimer were expressed in E. coli BL21 (DE3) by induction with 0.5 mM isopropyl beta-thiogalactopyranoside at an OD600 of 0.5-0.8 in liquid culture (LB-medium) for 5h at 37°C. E. coli
35 cells were the harvested by centrifugation and washed to remove the culture medium.

LB-medium: 10g sodium chloride, 10g peptone, 5g yeast extract, pH 7.5 with NaOH, autoclaved prior to use.

Purification. Recombinant Bet v 1-polymers were expressed as inclusion bodies and isolated as described (Vrtala et al., "Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p 2, Phl p 5)", J. Allergy Clin. Immunol. 97 (1996) 781-786. Inclusion bodies were solubilized with 8M urea, 10mM Tris, pH 8, 1mM EDTA, 5mM beta-mercaptoethanol, diluted with 10mM Tris, pH 8, to a concentration of 6M urea and centrifuged for 15min at 10,000g to remove insoluble material. The supernatant, containing the recombinant protein, was dialyzed to a final concentration of 2M urea. After centrifugation (15min, 10,000g), the supernatant was applied to a column packed with DEAE Sepharose (Pharmacia Biotech AB, Uppsala, Sweden), and the protein was eluted with a 0-0.5M NaCl-gradient. Fractions, containing the recombinant protein which was > 80% pure, were dialyzed against 6M urea, 10mM NaH₂PO₄, pH 4.8, and rechromatographed on a column packed with SP Sepharose (Pharmacia Biotech AB, Uppsala, Sweden). Fractions, containing recombinant Bet v 1-dimer or recombinant Bet v 1-trimer of > 95% purity were dialyzed against 10mM Tris, pH 7.5 and stored at -20°C until used.

Results of studies on Bet v 1 polymers

Construction of the Bet v 1 polymers. It is referred to the scheme with sequences and vector figures at the end of the descriptive part. The Bet v 1-cDNA (Breiteneder et al., EMBO J. 8 (1989) 1935-1938) was PCR-amplified with oligonucleotide primers containing different restriction enzyme cleavage sites. The PCR-products were then ligated as indicated in the scheme and subcloned into the plasmid pET-17b (Novagen, Madison, USA).

Figure 1. Coomassie stain d SDS-PAGE gel showing purified recombinant Bet v 1-monomer and Bet v 1-polymers

Lane M: Molecular weight marker; lane 1 contains 3µg purified, recombinant Bet v 1 monomer, lane 2 3µg purified, recombinant Bet v 1-dimer, and lane 3 3µg purified recombinant Bet v 1-trimer.

Result: The purified proteins were more than 95% pure. The dissolved proteins were separated from insoluble material by high speed centrifugation prior to loading the samples.

10

Figure 2. IgE-reactivity of birch-pollen allergic patients with nitro-cellulose-blotted purified recombinant Bet v 1-monomer, dimer and trimer.

Purified recombinant Bet v 1-monomer, dimer and trimer were separated by SDS-PAGE and blotted onto nitro-cellulose. Sera from 8 different birch pollen allergic patients (lanes 1-8) and serum from a non-allergic person (lane 9) were used to detect the blotted allergens. Bound IgE was detected with ¹²⁵I labelled anti-human >IgE antibodies (Pharmacia & Upjohn Diagnostics, Uppsala, Sweden) and visualised by autoradiography.

Result: The IgE-binding capacity of nitrocellulose-blotted Bet v 1-polymers was comparable to that of Bet v 1-monomer.

Figure 3: Determination of IgE-reactivity of sera from birch pollen allergic patients with Bet v 1-monomer and polymers by ELISA.

Sera from 4 birch-pollen allergic patients (A-D) were diluted 1:2 (1), 1:10 (2), 1:20 (3), 1:40 (4) and 1:80 (5) and tested for IgE-reactivity with purified, recombinant Bet v 1-monomer, Bet v 1-dimer and Bet v 1-trimer. The OD-values are displayed on the y-axis.

Result: Serum IgE from allergic patients bound to Bet v 1-polymers in a comparable manner as to Bet v 1-monomer.

35

Figur 4. Inhibition of IgE-binding to r combinant Bet v 1-monomer using Bet v 1-polymers.

Sera from 4 birch-pollen allergic patients (A-D) were preincubated with different concentrations (5µg, 500ng, 50ng and 5ng) of purified, recombinant Bet v 1-monomer, Bet v 1-dimer and Bet v 1-trimer. The preincubated sera were then tested for IgE-reactivity to purified, recombinant Bet v 1-monomer by ELISA. The optical densities (OD) are displayed on the y-axis.

- 10 **Result:** IgE-binding to Bet v 1-monomer is inhibited by increasing concentrations of the Bet v 1-polymers in a dose dependent manner. The amounts of Bet v 1-polymers needed for inhibition at certain concentrations (50 ng versus 5 ng) was however approximately tenfold higher compared to the
- 15 monomer.

Figure 5. Serum IgG₁-reactivity of Bet v 1-polymer immunized mice with recombinant Bet v 1.

- 8 Balb/c mice were immunized monthly with 5µg purified, recombinant Bet v 1-dimer and Al(OH)₃ as adjuvant, 8 Balb/c mice were immunized monthly with 5µg purified, recombinant Bet v 1-trimer-Al(OH)₃ and blood samples were taken after each immunization. Serum samples obtained after weeks 19 and 25 of immunization and serum taken before immunization (preimmune serum 0 =) were diluted 1:1000 and tested for IgG₁-reactivity with purified, recombinant Bet v 1-monomer in an ELISA. The symbols represent the OD-values that correspond to the IgG₁-binding of the 8 different Bet v 1-dimer or Bet v 1-trimer mice.

- 30 **Result:** The Bet v 1-polymers are able to induce high levels of IgG₁-antibodies, which crossreact with Bet v 1-monomer.

Figure 6. Capacity of recombinant Bet v 1-polymers to induce histamine release.

- 35 Granulocytes from a birch pollen allergic patient were incubated with increasing concentrations (0.01 µg/ml, 0.1 µg/ml, 1 µg/ml and 10 µg/ml) of purified, recombinant Bet v

1-monomer, Bet v 1-dimer, Bet v 1-trimer, Bet v 1-tetramer and anti-IgE antibodies as positive control. Histamine release in the cell free supernatant was measured by RIA (Immunotech, Marseille) and is expressed as percentage of total histamine release.

Result: Bet v 1-dimer induced a slightly reduced histamine release from patients' basophils compared to the monomer, whereas Bet v 1-trimer and tetramer had an approximately 100 fold reduced capacity to induce histamine release. In the donors tested, Bet v 1-monomer induced maximal histamine release at a concentration of 0.01 µg/ml, Bet v 1-trimer and tetramer at a concentration of 1 µg/ml.

Table 1. Proliferation of Bet v 1 specific T-cell clones with recombinant Bet v 1-polymers.

The full table is given at the end of the descriptive part. T-cell clones from different pollen allergic donors (column 2 shows the initials of the donors) with specificity for different Bet v 1 epitopes (in column 1 the position of the epitopes are indicated) were incubated with purified, recombinant Bet v 1-monomer (column 4), Bet v 1-dimer (column 5), Bet v 1-trimer (column 6) and Bet v 1-tetramer (column 7). As negative control, clones were tested with medium alone (column 3). Proliferation was determined by ³H Thymidine uptake and is displayed as counts per minute (cpm) (columns 3-7).

Result: Bet v 1-polymers and Bet v 1-monomer induced comparable proliferation of specific T cell clones.

Table 2. Skin testing with recombinant Bet v 1-monomer and polymers.

The full table is given at the end of the descriptive part. 6 birch-pollen allergic individuals and 4 non-allergic control individuals were skin prick tested on their forearms with natural birch pollen extract, histamine as positive control and with 10µg/ml and 100µg/ml of purified, recombinant Bet v 1-monomer, Bet v 1-dimer and Bet v 1-

trimer. The mean wheal diameters (DM) are displayed in the table.

Result: Bet v 1-dimer induced an approximately 10-fold reduced skin reaction in allergic patients compared to Bet v 1-monomer, whereas Bet v 1-trimer induced in some patients no wheal reactions at all, up to a concentration of 100 µg/ml. The wheal reaction increased dose dependently with the protein concentrations. The non-allergic control individuals displayed only skin reactions with histamine but not with the Bet v 1-preparations. Both the histamine release assays and the skin tests indicate that the Bet v 1-polymers have a greatly (up to 100 fold) reduced anaphylactic activity compared to Bet v 1-monomer. The reduction of anaphylactic potential is proportional to the degree of polymerization.

15

Summary - studies on Bet v 1 polymers.

We expressed in pET 17b plasmids (Novagen, Madison, USA) Bet v 1 as dimer, trimer and tetramer. The Bet v 1-polymers were expressed at high levels in E. coli BL21 (DE3) (Novagen, Madison, USA) and purified to homogeneity. The Bet v 1-polymers retained their IgE-binding capacity, as was shown by immunoblotting and by ELISA. T-cell clones from birch allergic donors, with specificity for Bet v 1 proliferated upon incubation with all the polymers, indicating that the polymers contain the relevant T-cell epitopes of Bet v 1. Bet v 1-trimer and tetramer had an approximately 100 fold reduced capacity to induce histamine release from patients' basophils and a greatly reduced anaphylactic potential as evaluated by skin testing. Because of the reduction of their anaphylactic activity the Bet v 1-polymers may be considered as safe tools for specific immunotherapy of tree pollen and associated food allergy. Allergic patients may be treated with high doses of these derivatives with reduced risk of anaphylactic side effects. The difference of the recombinant polymers to non-anaphylactic T-cell epitope containing allergen derivative is that they contain the IgE-binding sites but have a reduced anaphylactic potential.

Example 2. Mapping the binding site of antibodies in Bet v 1.

5

Figure 7: Two monoclonal anti-Bet v 1-antibodies (moAb A and B) were used together with three synthetic Bet v 1-derived peptides in ELISA. The sequences of the three peptides are shown in the lower part of the figure and correspond to aa
10 49-60 (p17), aa 52-63 (p18) and aa 55-66 (p19) of Bet v 1. The peptides were tested for binding to the two Bet v 1 specific monoclonals. The OD values are displayed on the y-axis. Both moAbs bind to the peptides p18 and p19, which are mapped to the first half of Bet v 1.

15

Table 3. The full table is given at the end of the descriptive part. Monoclonal anti-Bet v 1 antibodies (A,B) inhibit binding of human IgE to recombinant Bet v 1. Dot-blotted Bet v 1 was preincubated with MoAb A and B prior to
20 probing with serum IgE from 60 Bet v 1 allergic individuals. Bound IgE was detected with ^{125}I -labelled anti-human IgE antibodies and quantified by gamma-counting. Inhibition of IgE binding was determined as follows:

$$100 - (\text{cpm}_1 / \text{cpm}_2) 100 = \% \text{inhibition}$$

25 cpm_1 = count per minutes for incubation with moAb cpm_2 = count per minutes for incubation buffer

The % inhibition of IgE-binding compared to preincubation with buffer is displayed in the table.

30

Example 3. Two non-anaphylactic recombinant fragments of Bet v 1

See further Vrtala et al., "Conversion of the major birch
35 pollen allergen, Bet v 1, into two non-anaphylactic T cell epitope containing fragments", J. Clin. Invest. 99(7) April 1997) 1673-1681.

METHODS

Sera from allergic patients, antibodies, protein extracts and E. coli strains. Sera from birch pollen allergic

5 patients and control individuals were characterized by RAST and testing with recombinant allergens as described (Valenta et al., J. Allergy Clin. Immunol. 88 (1991) 889-894; Valenta et al., Int. Arch. Allergy Immunol. 97 (1992) 287-294). In addition, all patients were characterized by case history
10 and skin prick test. The mouse monoclonal antibody moab 14 with specificity for aa 40-65 of Bet v 1 is described (Lebecque et al., J. Allergy Clin. Immunol. 99(3) (1997) 374-384). Natural birch pollen extract was prepared as described (Vrtala et al., Int. Arch. Allergy Immunol. 102
15 (1993) 160-169). Plasmid pET-17b containing the ampicillin resistance and a T7 promotor was obtained from Novagen, Madison, USA. Recombinant Bet v 1 fragments were expressed in λ DE3 lysogens of E. coli strain BL21 (F⁻ ompTr_B-m_B-) (Studier et al., Meth. Enzymol. 185 (1990) 60-89).

20

Expression of Bet v 1 (aa 1-74, aa 75-160) fragments in E. coli. Recombinant Bet v 1 fragments (aa 1-74, aa 75-160) were generated to maintain the epitopes (aa 40-65) of murine monoclonal antibodies which inhibited binding of allergic
25 patients IgE to Bet v 1 (Lebecque et al., J. Allergy Clin. Immunol. 99(3) (1997) 374-384) and in order to preserve major T-cell epitopes which had been mapped using overlapping peptides synthesized according to the Bet v 1 sequence (Ebner et al., J. Immunol. 150 (1993) 1047-1054).
30 The cDNAs coding for fragment aa 1-74 and aa 75-160 were obtained by PCR amplification of the Bet v 1 cDNA using the following oligonucleotide primers (Pharmacia Biotech AB, Upsala Sweden):

35 Bet v 1 (aa 1-74)

Sequence Id No 9:

5'GGG AAT TCC ATA TGG GTG TTT TCA ATT AC3'

Sequence Id No 10:

5'CGG GGT ACC TTA CTC ATC AAC TCT GTC CTT3'

Bet v 1 (aa 75-160)

5 Sequence Id No 11:

5'GGG AAT TCC ATA TGG TGG ACC ACA CAA ACT3'

Sequence Id No 12:

5'CGG GGT ACC TTA GTT GTA GGC ATC GGA3'

10 The Eco RI sites which were incorporated in the first primers are underlined, Nde I and Kpn I sites are in italics. To improve subcloning efficiency, PCR-products were first cut with Eco RI and Kpn I, purified by preparative agarose gel electrophoresis, subcloned into Eco RI and Kpn I
15 site of plasmid pET-17b (Novagen, Madison, USA) and transformed into E. coli BL21 (DE3) (Novagen, Madison, USA) by electroporation. Inserts were then excised with Nde I/Kpn I and subcloned again in plasmid pET-17b and transformed. Colonies expressing the correct fragments were identified by
20 immunoscreening using mab 14 for Bet v 1 aa 1-74 and a rabbit anti-Bet v 1 C-terminal antiserum for Bet v1 aa 75-160. DNA from positive clones was isolated using Qiagen tips (Quiagen, Hilden, Germany) and both DNA strands were sequenced according to Sanger using a T7 polymerase
25 sequencing kit (Pharmacia Biotech AB, Uppsala, Sweden) and ³⁵S dCTP (NEN, Stevehage, UK) (24). Recombinant Bet v 1 (aa 1-74 and Bet v1 (aa 75-160) were expressed in E. coli BL21 (DE3) by induction with 0.5 mM IPTG at an OD600 of 0.5-0.8 in liquid culture for 5 hours at 37°C.

30

Purification of recombinant Bet v1 (aa 1-74) and Bet v1 (aa 75-160). Bet v1 (aa 1-74) and Bet v1 (aa 75-160) were expressed in inclusion bodies isolated as described (Vrtala et al., J. Allergy Clin. Immunol. 97 (1996) 781-787).

35 Inclusion bodies were solubilized with 8M urea, 10 mM Tris, pH 8, 1 mM EDTA (ethylenediaminetetraacetic acid), 5 mM β-mercaptoethanol, diluted with 10 mM Tris, pH 8 to a

WO 99/16467

concentration of 6 M urea and centrifuged for 15 minutes at 10,000xg to remove insoluble material. The supernatant containing the recombinant protein was dialyzed to a final concentration of 2M urea. Following centrifugation (15min, 5 10,000xg), the supernatant was applied to a column packed with DEAE (diethylaminoethyl) Sepharose (Pharmacia Biotech AB) and the protein eluted with a 0-0.5M NaCl concentration gradient. Fractions, containing the recombinant protein which was more than 80% pure, were dialyzed against 6M urea, 10 10mM NaH₂PO₄, pH 4.8 and rechromatographed on a column packed with SP Sepharose (Pharmacia Biotech AB). Fractions containing recombinant Bet v 1 (aa 1-74) or recombinant Bet v 1 (aa75-160) of greater than 95% purity, were dialyzed against 10mM Tris, pH 7.5 and lyophilized until used.

- 15 **IgE binding capacity of recombinant Bet v 1 and Bet v 1 fragments.** Purified recombinant Bet v 1 and Bet v 1 fragments (aa 1-74, aa 75-160) were tested for IgE-binding capacity by Western blotting and in dot blot assays. For 20 immunoblotting, approximately 1 µg/cm purified protein was separated by SDS-PAGE (Fling et al., Anal. Biochem. 155 (1986) 83-88) and blotted onto nitrocellulose according to Towbin (Towbin et al., Proc. Natl. Acad. Sci. USA 76 (1979) 4350-4353). To avoid denaturation of the proteins, dot blot 25 experiments were performed in parallel. 1 µg of purified recombinant Bet v 1, 1 µg of each Bet v 1 fragment and 1 µg of bovine serum albumin and human serum albumin (HSA) (negative controls) were dotted on nitrocellulose strips. Nitrocellulose strips containing Western blotted allergens 30 or the dot blotted proteins were incubated with serum IgE from allergic individuals, non-allergic control individuals and buffer without addition of serum as described (Valenta et al., J. Exp. Med. 175 (1992) 377-385). Bound IgE antibodies were detected with 125I labelled anti-human IgE 35 **Results:** Sera of birch pollen allergic patients reacted with recombinant Bet v 1 but not with Bet v 1 fragments. Sera of

grass pollen allergic individuals reacted neither with recombinant Bet v 1 nor with the recombinant Bet v 1 fragments.

- 5 **Circular dichroism** showed that the two Bet v 1 fragments showed no tendency to fold, even in the presence of each other.

Histamine release experiments. Granulocytes were isolated
10 from heparinized blood of birch pollen allergic individuals by dextran sedimentation (Valent et al., Proc. Natl. Acad. Sci. USA 86 (1989) 5542-5547). Cells were incubated with different concentrations (0.001µg/ml-10µg/ml) of purified
15 recombinant Bet v 1, recombinant Bet v 1 fragments (aa 1-74, aa 75-160) separately and in equimolar mixture, or anti-human IgE antibodies. Histamine released in the supernatant was measured by radioimmunoassay (RIA) (Immunotech, Marseille, France) (Valenta et al., J. Allergy Clin. Immunol. 91 (1993) 88-97). Total histamine was determined in cell lysates after
20 freeze thawing. Results were obtained as mean values from triplicate determinations and expressed as percentage of total histamine release.

Results: Recombinant Bet v 1 fragments have approximately 1000 fold reduced capacity to induce histamine release from
25 patients basophils compared to recombinant Bet v 1. An equimolar mixture of both Bet v 1 fragments did not induce significant release of histamine compared to each of the tested fragments.

30 **Skin testing.** Skin prick tests were performed on the individuals' forearms by placing 20 µl of each solution (Pauli et al., J. Allergy Clin. Immunol. 97 (1996) 1100-1109; Menz et al., Clin. Exp. Allergy 26 (1996) 50-60). Recombinant Bet v 1 and recombinant Bet v 1 fragments were
35 freshly dissolved in a 0.9% w/v sterile sodium chloride solution at concentrations of 100µg/ml and 10µg/ml. As controls birch pollen SQ (standard quality) extract, sodium

- chloride solution (negative control) and histamine hydrochloride (positive control) (ALK, Horsholm, Denmark) were used. Each drop was pricked with a fresh prick lancette (ALK, Horsholm, Denmark) and results were recorded after 20 minutes with a ball point pen by transferring the wheal area with a tape paper and by photography. The mean wheal diameter (D_m) was calculated by measuring the maximal longitudinal diameter (D_9) and the maximal transversal diameter (d) according to the formula $(D+d)/2=D_m$.
- 10 **Results:** The two recombinant Bet v 1 fragments, neither alone nor in combination, do not elicit anaphylactic skin reactions compared to the intact recombinant Bet v 1.

Table 1: Proliferation of Bet v 1 specific T-cell clones with recombinant Bet v 1-polymers.

1	2	3	4	5	6	7
Epitop Bet v 1	TCC	Control	Bet v 1	Bet v 1- dimer	Bet v 1- trimer	Bet v 1- tetramer
1-15	CGE 147	15567	47570	97939	67299	79741
1-18	HC 26/II	1264	9977	32667	14170	22178
10-27	WF 110/III	87	6402	12571	5823	9542
10-27	WF 110/III	146	3575	13340	5428	6961
10-27	WF 121/III	287	3914	22099	5117	13000
11-27	TF 7B	359	10492	42352	9869	29900
35-48	HC 3/III	40.7	10499	21301	15761	25609
64-75	CGE 110	612	107103	121178	96135	117930
64-75	CGE 31	2937	71176	55728	38955	67625
64-75	CGE 33	3096	99633	85438	80077	91755
77-93	WF 29R	143	12638	28579	14576	14677
77-93	GZ 17M	172	61463	90586	54988	84237
88-10	CGE 34	515	16045	20531	14176	15217
93-110	TF 1M	438	21423	29741	11500	23454
106-120	WF 9/III	305	43203	81605	32735	65592
109-120	WD 7/III	130	53362	41875	50489	48601
110-128	HC 33/II	134	18099	46022	17917	42051
112-123	WF 112/III	85	10494	12778	7585	11106
112-123	WF 97/III	91	4569	6884	3352	5950
127-138	GZ 10A	182	3347	8379	3227	6645
141-156	TF 10A	215	4862	4438	2232	57
141-156	RR4R	1416	88361	85594	102303	117122
141-156	SAZ 10/IV	612	5121	3830	5207	3979

Table 2: Skin testing with recombinant Bet v 1-monomer and polymers

Individual	Histamine	birch	Bet v 1 monomer 10µg/ml	Bet v 1 monomer 100µg/ml	Bet v 1 dimer 10µg/ml	Bet v 1 dimer 100µg/ml	Bet v 1 trimer 10µg/ml	Bet v 1 trimer 100µg/ml
<hr/>								
birch pollen								
allergic patients								
MS	8	5.5	4	7	3	6	0	0
SF	6	7	8	12	7.5	8	2	5.5
PSt	8	7	6.5	16	6	7	2	4.5
SO	6.5	5.5	5.5	14	0	4.5	0	3.5
SS	4.5	8	5.5	9	0	4	0	0
MD	5.5	9.5	7	11.5	4.5	7	0	5
non-allergic								
controls								
TB	6	0	0	0	0	0	0	0
UR	8.5	0	0	0	0	0	0	0
CD	6.5	0	0	0	0	0	0	0
TL	9	0	0	0	0	0	0	0


Table 3:

patient #	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
inhibition of moAb A	49	-	-	57	93	96	-	41	-	41	27	-	29	47	-
IgE binding															
in %	96	-	-	45	-	97	-	31	-	45	24	-	-	26	-
patient #	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30
inhibition of moAb A	19	21	35	-	36	-	-	10	20	51	30	-	30	-	55
IgE binding															
in %	24	25	12	14	21	-	-	-	22	31	33	-	24	-	50
patient #	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45
inhibition of moAb A	10	28	8	18	23	23	3	-	46	22	-	8	30	80	33
IgE binding															
in %	4	90	5	59	87	97	13	-	18	19	65	80	10	94	17
patient #	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60
inhibition of moAb A	-	6	54	30	36	12	-	-	-	72	31	1	12	38	-
IgE binding															
in %	-	31	97	-	35	8	-	-	-	67	41	-	10	28	-

CONSTRUCTION OF THE BET V 1 POLYMERS**5 Bet v 1-Dimer**

Sequence Id Nos 13 and 14, respectively:

ATG.....AAC TTG GTA CCG ATG.....AAC TAA
 10 Met.....Asn Leu Val Pro Met.....Asn End
 Bet v 1 Bet V 1

**Bet v 1-Trimer**


30 Sequence Id Nos 15 and 16, respectively:

ATG.....AAC TTG GTA CCG ATG.....AAC CCA CTA GTA ATG.....AAC
Met.....Asn Leu Val Pro Met.....Asn Pro Leu Val Met.....Asn
 Bet v 1 Bet v 1 Bet v 1

35 GGA TTC TGC AGA TAT CCA TCA CAC TGG CGG CCG CTC GAG CAG ATC
 Glu Phe Cys Arg Tyr Pro Ser His Trp Arg Pro Leu Glu Gln Ile

CGG CTG CTA ACA AAG CCC GAA AGG AGG CTG AGT TGG CTG CTG CCA
 40 Arg Leu Leu Thr Lys Pro Glu Arg Lys Leu Ser Trp Leu Leu Pro

CCG CTG AGC AAT AAC TAG
 Pro Leu Ser Asn Asn End




5 **Bet v 1-tetramer**

Sequence Id Nos 17 and 18, respectively:

ATG.....AAC TTG GTA CCG ATG.....AAC CCA CTA GTA ATG.....AAC
Met.....Asn Leu Val Pro Met.....Asn Pro Leu Val Met.....Asn
 10 Bet v 1 Bet V 1 Bet v 1

GAA TTC ATG.....AAC TAA
 Glu Phe Met.....Asn End
 Bet v 1

15



Claims

1. An immunogen derived from a protein allergen,
characterized in that said immunogen comprises:
 - 5 a) a polymeric form of a non-anaphylactic immunogenic recombinant fragment of the protein allergen, said fragment containing an IgG epitope partly but not wholly overlapping an IgE epitope of the protein allergen, in which polymeric form said fragment constitutes the monomeric units; or
 - 10 b) a recombinant polymeric form of said protein allergen in which the protein allergen constitutes the monomeric units.
2. The immunogen according to claim 1, **characterized** in
15 that the polymeric form of said fragment is recombinantly produced.
3. The immunogen according to claim 1 or 2, **characterized**
in that said monomeric units are separated from each other
20 by an oligopeptide linker, typically consisting of a 1-30 amino acid residue that may be hydrophilic.
4. The immunogen according to any one of claims 1 to 3,
characterized in that said immunogen also contains a carrier
25 for said polymeric forms in (a) and (b), respectively.
5. The immunogen according to any one of claims 1 to 4,
characterized in that the protein allergen is Bet v 1.
- 30 6. The immunogen according to any one of claims 1 to 5,
characterized in that the number of the monomeric units is an integer selected from 2-10.
7. The use of the immunogen according to any one of claims
35 1 to 6 for in vitro diagnosis of type I allergy in a mammalian individual.

8. The use according to claim 7, **characterized** in that the number of monomeric units is an integer selected from 2-10.

5 9. The use of the immunogen according any one of claims 1 to 6 for the preparation of a medicament to be used in the hyposensitization of a mammalian individual suffering from a type I allergy, or for the preparation of a reagent to be used in diagnosis in vivo of type I allergy.

10

10. The use according to claim 9, **characterized** in that the number of monomeric units is an integer selected from 2-10.

11. A method for the hyposensitization of a mammal
15 suffering from IgE mediated allergy against a protein allergen, which method comprises the step of presenting the immune system of the mammal in vivo to an effective amount of an immunogen hyposensitizing the mammal against the allergen, **characterized** in that the immunogen comprises:

20 a) a polymeric form of a non-anaphylactic immunogenic recombinant fragment of the protein allergen, said fragment containing an epitope partly but not wholly overlapping an IgE epitope of the protein allergen, in which polymeric form said fragment constitutes the monomeric units; or

25 b) a recombinant polymeric form of said protein allergen in which the protein allergen constitutes the monomeric units.

12. The method according to claim 11, **characterized** in that
30 the immunogen is a polymeric form of said fragment and is recombinantly produced.

13. The method according to claim 11 or 12, **characterized**
in that said monomeric units are separated from each other
35 by an oligopeptide linker, typically consisting of a 1-30 amino acid residue that may be hydrophilic.

14. The method according to any one of claims 11 to 13,
characterized in that said immunogen also contains a carrier
for the polymeric forms in (a) and (b), respectively.
- 5 15. The method according to any one of claims 11 to 14,
characterized in that the protein allergen is Bet v 1.
16. The method according to any one of claims 11 to 15,
characterized in that the number of monomeric units is an
10 integer selected from 2-10.

1 / 7




Fig. 1

2/7




Fig. 2

3 / 7




Fig. 3

4/7





Fig. 4

5/7






Fig. 6

7/7




Fig. 7

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/01765

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 39/35, C07K 14/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K, C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Journal of clinical investigation, Volume 99, No 7, April 1997, Susanne Vrtalaet al, "Conversion of the Major Birch Pollen Allergen, Bet v 1, into Two Nonanaphylactic T Cell Epitope-containing Fragments", page 1673 - page 1681, see Table 1 and page 1679 - 1680	
Y	--	1-10
A	WO 9603106 A2 (UNIVERSITY OF MANITOBA), 8 February 1996 (08.02.96), see Table 1, examples 2 and 3, pages 7-9, 12-15, page 24, lines 33-36	1,7,9
	--	

☒ Further documents are listed in the continuation of Box C.
 ☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

27 January 1999

Date of mailing of the international search report

29-01-1999

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Carl-Olof Gustafsson

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/01765

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9410194 A2 (BIOMAY PRODUKTIONS- UND HANDELSGESELLSCHAFT M.B.H.), 11 May 1994 (11.05.94), see pages 5-6 --	5
A	WO 9534578 A1 (PHARMACIA AB), 21 December 1995 (21.12.95) --	1
A	US 5449669 A (DEAN D. METCALFE ET AL), 12 Sept 1995 (12.09.95), see column 11, line 28 - column 12 --	1
Y	Dialog Information Service, file 154, MEDLINE, Dialog accession no. 08362396, Medline accession no. 98055718, Tamborini E et al: "Biochemical and immunological characterization of recombinant allergen Lol p 1"; Eur J Biochem, Nov 1 1997, 249 (3)p886-94 --	1-10
A	Dialog Information Services, file 154, MEDLINE, Dialog accession no. 08635889, Medline accession no. 96245983, Zhang L et al: "Multiple B- and T-cell epitopes on a major allergen of Kentucky Bluegrass pollen"; & Immunology, Feb 1996, 87 (2) p283-90 --	1,7,9
Y	WO 9724139 A1 (UNIVERSITY OF ARKANSAS), 7 October 1997 (07.10.97), see pages 73-74, pages 125-129, pages 149-150 and in particular page 127, lines 7-13 --	1-10
Y	WO 9211029 A1 (THE JOHNS HOPKINS UNIVERSITY), 9 July 1992 (09.07.92), see claim 1 and examples 5 and 12 and pages 71-73 -- -----	1-10

INTERNATIONAL SEARCH REPORT
Information on patent family members

21/12/98

International application No.
PCT/SE 98/01765

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9603106 A2	08/02/96	AU 3338195 A	22/02/96
WO 9410194 A2	11/05/94	AU 5411594 A	24/05/94
WO 9534578 A1	21/12/95	AU 2759895 A	05/01/96
		EP 0763059 A	19/03/97
		JP 10501417 T	10/02/98
		SE 9402089 D	00/00/00
US 5449669 A	12/09/95	NONE	
WO 9724139 A1	07/10/97	AU 7243396 A	28/07/97
		EP 0873135 A	28/10/98
WO 9211029 A1	09/07/92	CA 2098281 A	18/06/92
		EP 0572443 A	08/12/93
		JP 6503833 T	28/04/94